A cost-utility analysis of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction
ConclusionsSildenafil treatment of erectile dysfunction was a cost-effective alternative compared to tadalafil and vardenafil, as well as compared to a “no-treatment” option. Treating a diabetic population is less cost-effective for all PDE5 inhibitors and was associated with greater uncertainty.
Source: The European Journal of Health Economics - Category: Health Management Source Type: research
More News: Cialis | Diabetes | Economics | Endocrinology | Erectile Dysfunction | Health Management | Levitra | Norway Health | Study | Viagra